Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti
Medtronic, Inc. · Decision date Nov 7, 2026
What did the FDA decide?
FDA lists this action as a 30-Day Notice supplement to PMA P130021/S188 for Medtronic’s Evolut FX delivery catheter system within the Evolut FX transcatheter aortic valve system. The database record frames it as a process change, not a new PMA and not a new approval of the whole system.
The only changed item described in the supplied text is “the introduction of an automated vision system for the detection of flash.” The record does not say what “flash” refers to, where the vision system is used in the manufacturing chain, or whether any device design, indication, or clinical evidence changed.
FDA approval order statement
the introduction of an automated vision system for the detection of flash
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 7, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P130021/S188
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NPT
- Decision code
- OK30
- Decision date
- Nov 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- Medtronic, Inc.
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P130021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P130021 · Original PMA
MEDTRONIC COREVALVE SYSTEM
P130021/S188 received
Application receipt date recorded by FDA.
P130021/S188 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P130021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MEDTRONIC COREVALVE SYSTEMP130021 | Medtronic, Inc. | PMA approval | Jan 17, 2014 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S005 | JenaValve Technology, Inc. | PMA supplement | Oct 13, 2026 | FDA |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 710 Medtronic Pkwy., Miinneapolis, MN, 55432
Sources and methodology
- Original FDA record: P130021/S188
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records